Trastuzumab brengitecan vs Tucatinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HER2-Positive Breast Cancer
Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline
Trastuzumab brengitecan
Developed by Sichuan Baili Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT06891833 (registry estimate)
No aligned efficacy figure on record for this race.
Tucatinib
Marketed by Pfizer and partners
NCT03975647 · Phase 3 · active, not recruiting
This was a randomized, quadruple-masked, placebo-controlled trial of 466 patients, with progression-free survival as the primary endpoint. The primary comparison reached statistical significance in favor of tucatinib (hazard ratio 0.759, p=0.0163).
Next expected readout: December 2026 · NCT06016387 (registry estimate)
Reported efficacy
Progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (Up to approximately 3 years): HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. (met)
Result source: NCT05132582
Results for HER2-Positive Breast Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Trastuzumab brengitecan: no structured comparison results are available for HER2-Positive Breast Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tucatinib
show 7 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Available safety results
Tucatinib
| Dropout rate | 34.6% NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more resultn/a: no completion milestone NCT02614794 · Phase 2 · combination |
|---|---|
| Discontinued due to AEs | — NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more result— NCT02614794 · Phase 2 · combination |
| Serious AEs | 30.3% NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more result30.7% NCT02614794 · Phase 2 · combination |
| Most frequent reported AEs | nausea 65.4% (placebo 48.5%) diarrhoea 56.7% (placebo 26.6%) fatigue 48.9% (placebo 36.5%) NCT03975647 · Phase 3 · combination · Breast Cancer, HER2-Positive Breast Cancer · phase 3 show 1 more resultdiarrhoea 81.7% (placebo 53.8%) palmar-plantar erythrodysaesthesia syndrome 65.6% (placebo 53.3%) nausea 60.1% (placebo 44.2%) NCT02614794 · Phase 2 · combination |
Colorectal Cancer
Shared mechanism: HER2 · full Colorectal Cancer pipeline
Trastuzumab brengitecan
Developed by Sichuan Baili Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07730489 (registry estimate)
No aligned efficacy figure on record for this race.
Tucatinib
Marketed by Pfizer and partners
NCT03043313 · Phase 2 · completed
The study included a randomized cohort and an objective tumor-response endpoint assessed by blinded independent central review, but treatment assignment was open-label and the primary analysis pooled a non-randomized cohort with the randomized combination-therapy cohort rather than testing a prespecified arm-to-arm comparison. The reported primary response result was therefore descriptive rather than a statistically tested comparison, supporting moderate rather than strong evidence.
Next expected readout: December 2026 · NCT05382364 (registry estimate)
Reported efficacy
Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5) (not_applicable)
Result source: NCT03043313
Results for Colorectal Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Trastuzumab brengitecan: no structured comparison results are available for Colorectal Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Trastuzumab brengitecan's landscape · Tucatinib's landscape